Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

On the research front last week, China-based biotech Remegen released positive Phase III results for its telitacicept in ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...